Hair Loss Guide

Is Dutasteride Better Than Finasteride for Hair Loss?

Both finasteride and dutasteride work by blocking the enzyme that converts testosterone into

Both finasteride and dutasteride work by blocking the enzyme that converts testosterone into

DHT, the hormone responsible for follicle miniaturization. But they don’t function exactly the same. Dutasteride is a more powerful DHT inhibitor, and for some men, that additional potency makes a meaningful difference.

The Same Mechanism, Different Reach

Finasteride and dutasteride are both 5-alpha reductase inhibitors. The 5-alpha reductase enzyme exists in two main forms: Type I and Type II. Type II is the dominant form in the scalp and accounts for most DHT production in the hair follicle.

Finasteride selectively blocks Type II 5-alpha reductase. Dutasteride blocks both Type I and Type II.

The result is a clear difference in DHT suppression. In clinical studies:

That additional 20–25% reduction in DHT is the core argument for dutasteride in patients who are not responding adequately to finasteride or who have more aggressive hair loss patterns.

Bottom line

Dutasteride achieves steeper DHT suppression than finasteride by blocking both forms of 5-alpha reductase. The additional potency translates to measurable differences in clinical outcomes for many patients.

What the Clinical Evidence Shows

Dutasteride is not FDA-approved for hair loss in the United States. It is approved for benign prostatic hyperplasia at 0.5 mg. It is, however, approved for hair loss in South Korea and Japan, and it is widely prescribed off-label for androgenetic alopecia in the United States and elsewhere.

Here’s what the clinical data shows:

A 2006 study compared dutasteride at multiple doses (0.05, 0.1, 0.5, and 2.5 mg) against finasteride at 5 mg and placebo over 24 weeks. At the 0.5 mg and 2.5 mg doses, dutasteride significantly outperformed finasteride in total hair count and hair width at the vertex. 2.5 mg outperformed 0.5 mg, suggesting a dose-dependent response.

A 2014 randomized controlled trial compared dutasteride 0.5 mg to finasteride 1 mg over 26 weeks. Dutasteride produced significantly greater improvement in hair count, hair width, and global photographic assessment, with dutasteride outperforming finasteride at every time point measured.

A 2019 meta-analysis of randomized controlled trials found that dutasteride was consistently superior to finasteride in increasing hair count, with a mean difference of 13.3 hairs per cm² in favor of dutasteride.

Bottom line

The clinical evidence consistently shows dutasteride outperforming finasteride for hair count and hair width at standard doses. The difference is statistically and clinically significant.

Topical Dutasteride

Like finasteride, dutasteride is now available in topical formulations. Topical dutasteride delivers the drug directly to the scalp, concentrating the effect at the follicle level while reducing systemic absorption.

Topical dutasteride is not yet available as an FDA-approved product in the United States. It is available through compounding pharmacies by prescription.

Bottom line

Topical dutasteride provides a way to access the drug's potency at the scalp level with reduced systemic exposure. This is a meaningful option for men who want the effectiveness without the full systemic DHT suppression of the oral form.

Side Effect Profile: How They Compare

Both drugs carry a similar risk of side effects. The most discussed are sexual in nature: reduced libido, erectile dysfunction, and reduced ejaculate volume. In head-to-head studies, dutasteride has shown a similar rate of sexual side effects to finasteride, despite its greater potency.

The more important distinction between the two drugs is half-life. Finasteride has a half-life of about 6–8 hours. If a man experiences side effects and stops, the drug clears relatively quickly.

Dutasteride has a half-life of about five weeks. It accumulates in adipose tissue and takes four to six months to clear the body after stopping treatment. For men who experience side effects from dutasteride, this longer persistence may mean side effects take longer to resolve.

Bottom line

Both drugs have similar risks of side effects, despite dutasteride’s increased potency. Dutasteride's five-week half-life means side effects take longer to resolve after stopping.

Who Should Consider Dutasteride?

Dutasteride is generally considered in the following situations:

Bottom line

Dutasteride could be considered by men looking to escalate their finasteride treatment, who need aggressive treatment for rapid hair loss, or men looking to maximize their hair gains from the beginning of their treatment.

Dosing Considerations

Dutasteride is most commonly used at a 0.5 mg dose for hair loss. However, some studies have used doses up to 2.5 mg.

There is no consensus on the ideal topical dose. However, 0.02% topical dutasteride, used at 2 mL daily, equates to a 0.4 mg daily dose, matching the most frequently used oral dose.

Bottom line

0.5 mg daily is the most studied dose for hair loss, however up to 2.5 mg has been used orally. There is no consensus on the ideal topical dose, but 0.02% topical dutasteride, applied at 2 mL daily, equates to a 0.4 mg daily dose.

Combination Use With Minoxidil

As with finasteride, dutasteride works on the hormonal pathway and does not directly stimulate growth. Combining dutasteride with minoxidil addresses two separate mechanisms simultaneously.

There are no large-scale randomized trials directly comparing dutasteride plus minoxidil against finasteride plus minoxidil. Clinical experience suggests the combination is at least as effective as finasteride plus minoxidil and likely more effective for men with aggressive patterns.

Bottom line

Dutasteride plus minoxidil is an active area of clinical practice. Evidence supports the combination approach, though head-to-head data against finasteride plus minoxidil is limited.

The Bottom Line

Dutasteride suppresses DHT more completely than finasteride, about 90–95% versus 70%.

Clinical trials consistently show better hair count and hair width outcomes with dutasteride at standard doses. The side effect profile is similar, but dutasteride's five-week half-life means it persists longer in the body after stopping. Dutasteride is an appropriate choice for men who have not responded to finasteride and for those with aggressive patterns requiring stronger DHT suppression.

References & Citations
  1. Olsen, Elise A., et al. "The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride." Journal of the American Academy of Dermatology, vol. 55, no. 6, 2006, pp.
  2. 1014–1023.
  3. Gubelin Harcha, Walter, et al. "A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia." Journal of the American Academy of
  4. Dermatology, vol. 70, no. 3, 2014, pp. 489–498.
  5. Zhou, Zhifeng, et al. "Dutasteride versus finasteride for the treatment of male androgenetic alopecia: a short-term comparative study on scalp biopsy." Experimental and Therapeutic
  6. Medicine, vol. 20, no. 3, 2020, pp. 2621–2626.
  7. Dhurat, Rachita, et al. "An open-label randomized multicenter study assessing the noninferiority of a 0.1% finasteride topical solution compared with a 1 mg oral finasteride tablet in male androgenetic alopecia." Indian Dermatology Online Journal, vol. 11, no. 2, 2020, pp. 185–190.
  8. Kaufman, Keith D. "Androgens and alopecia." Molecular and Cellular Endocrinology, vol. 198, no. 1–2, 2002, pp. 89–95.
  9. Shapiro, Jerry, and Nina Otberg. Hair Loss: Principles of Diagnosis and Management of
  10. Alopecia. CRC Press, 2015.
  11. Eun, Hee Chul, et al. "Dutasteride 0.5 mg/d versus finasteride 1 mg/d in Korean men with male pattern hair loss: a 26-week, randomized, double-blind, multicenter trial." Journal of the
  12. American Academy of Dermatology, vol. 63, no. 2, 2010, pp. 252–259.